145020.KQ
Strong BuyUnloved QualityAI neutralHugel, Inc. · Healthcare · South Korea · $1.5B
KRW 182,800 -0.4% · close 8 Oct · scored 9 Oct
Unloved Quality: Strong and cheap; the market has not turned yet.
Read our full research report on 145020.KQ (Jun 2026), freeDoes StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Hugel is a Korean maker of botulinum toxin and hyaluronic acid fillers with high margins and a strong quality score, selling into a global aesthetics market that keeps growing. Insider buying and selling over the past 90 days roughly cancel out, momentum is weak, and there is no fresh news on US or China market share gains to show that growth is accelerating.
ABOUT HUGEL, INC.
Read
Hugel, Inc. is a leading South Korean medical aesthetics company that manufactures and distributes botulinum toxin, dermal fillers, and cosmetic products. The company's competitive moat is sustained by its dominant market share in South Korea and its expanding regulatory approvals in major global markets, including China, Europe, and the US. Hugel operates as a highly profitable, market-leading player in the global medical aesthetics industry.
FINANCIAL SUMMARY (KRW)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 281.7B | 319.7B | 373.0B | 425.1B | 14.7% | 480.3B | 514.1B | 642.4B | 22.9% |
| EPS (KRW) | 4,811 | 8,217 | 12,520 | 13,061 | 39.5% | 13,081 | 13,004 | 17,059 | 14.3% |
| Shares | 11.8M | 10.9M | 10.8M | 10.8M | -8.5% | 10.8M | — | — | — |
| Debt | 100.7B | 90.5B | 37.6B | 29.1B | -33.9% | 28.4B | — | — | — |
| Equity | 792.1B | 747.3B | 803.8B | 950.3B | 6.3% | — | — | — | — |
| Op CF | 80.6B | 117.7B | 149.1B | 150.1B | 23.0% | 181.7B | — | — | — |
| Inv CF | -191.8B | 43.2B | 42.4B | -48.7B | — | — | — | — | — |
| Fin CF | -51.4B | -187.1B | -172.1B | -21.7B | — | — | — | — | — |
Swung more than 73% of stocks we rank over the past year (58% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 145020.KQ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 145020.KQ | Hugel, Inc.(you) | $1.5B | 86 | Strong Buy |
| 214450.KQ | PharmaResearch Co., Ltd. | $2.5B | 82 | Strong Buy |
| 096530.KQ | Seegene, Inc. | $1.1B | 97 | Strong Buy |
| 326030.KS | SK Biopharmaceuticals Co., Ltd. | $4.4B | 60 | Hold |
| 048870.KQ | Synergy Innovation Co., Ltd. | $96M | 66 | Buy |
| 251120.KQ | BIO-FD&C Co.,Ltd. | $58M | 75 | Buy |
| 302440.KS | SK bioscience Co.,Ltd. | $2.1B | 15 | Strong Sell |
| 340450.KQ | GC Genome Corporation | $143M | 55 | Hold |
| 234690.KQ | GC WellBeing Corporation | $119M | 54 | Hold |
| 005690.KS | Pharmicell Co., Ltd. | $556M | 23 | Sell |
Peer medians: ROE -0.3% · P/E 17.6x · Gross margin 43.0%
Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.